<DOC>
	<DOC>NCT02980276</DOC>
	<brief_summary>The overall objective of the EMERGE trial is to determine whether metformin + usual care, compared to placebo + usual care (introduced at the time of initial diagnosis of GDM), reduces a) the need for insulin use, or hyperglycemia (primary outcome measure); b) excessive maternal weight gain; c) maternal and neonatal morbidities and, d) cost of treatment for women with Gestational Diabetes Mellitus.</brief_summary>
	<brief_title>A Clinical Trial of the Effectiveness of Metformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes, Gestational</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. Willing and able to provide written informed consent 2. Women aged 1850 3. Pregnancy gestation between 24 and 28 weeks 4. Singleton pregnancy as determined by scan 5. Positive diagnosis of Gestational Diabetes Mellitus on a OGTT according to IADPSG criteria if any one of the following are achieved: i) Fasting glucose &gt;/= 5.1mmol/l and &lt;7mmol/l, or ii) 1 hour post glucose load of &gt;/=10mmol/l, or iii) 2 hour post glucose load of &gt;/=8.5 mmol/l and &lt;11.1mmo/l 6. Resident in the locality and intending to deliver within the trial site 1. Women who have an established diagnosis of diabetes (Type 1, Type 2, Monogenic or secondary) 2. Women with a fasting glucose &gt; 7mmol/l or a 2h value &gt; 11.1 mmol/l 3. Multiple pregnancies (twins, triplets etc.) as determined by scan 4. Known intolerance to metformin 5. Known contraindication to the use of metformin which include: i) renal insufficiency (defined as serum creatinine of greater than 130 Âµmol/L or creatinine clearance &lt;60 ml/min), ii) moderate to severe liver dysfunction (alkaline phosphatase and alanine aminotransferase greater than 3 times the upper limit of normal, iii) shock or sepsis, and iv) previous hypersensitivity to metformin 6. Known fetal anomaly as determined by early or midtrimester scan 7. Known small for gestational age1 determined by early or midtrimester scan 8. Known gestational hypertension or preeclampsia or ruptured membranes 9. Subjects who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements 10. Women with significant gastrointestinal problems such as severe vomiting, Crohn's disease or colitis which will inadvertently affect absorption of the study drug 11. Women with congestive heart failure or history of congestive heart failure 12. Women with serious mental illness which would affect adherence to study medication or compliance with study protocol in the opinion of the investigator 13. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gestational Diabetes</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Pregnancy</keyword>
</DOC>